Holen Sie sich die Stockscreener-App
1.42
0.71%
0.01
Cocrystal Pharma Inc Aktie (COCP) Neueste Nachrichten
COCP stock touches 52-week low at $1.35 amid market fluctuations By Investing.com - Investing.com South Africa
COCP stock touches 52-week low at $1.35 amid market fluctuations - Investing.com Australia
What is Zacks Small Cap’s Estimate for COCP Q3 Earnings? - Defense World
COCP: Norovirus Challenge Study Planned for 2025… - MSN
Cocrystal Pharma, Inc. SEC 10-K Report - TradingView
Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs - TradingView
Cocrystal Pharma Pushes Forward with Antiviral Programs Despite $17.5M Loss - Stock Titan
Cocrystal Pharma Inc expected to post a loss of 53 cents a shareEarnings Preview - TradingView
Hepatitis C Virus Infection Pipeline 2025: FDA Updates, Therapy - openPR
Cocrystal Pharma (COCP) to Release Earnings on Thursday - Defense World
Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing - The Manila Times
Bird Flu Vaccine Stocks: 8 Companies Developing H5N1 Vaccines - Investing News Network
Life Sciences Investor Forum Agenda Announced for March 13th - Morningstar
Athira Pharma Stock Price, Quotes and Forecasts | NASDAQ:ATHA - Benzinga
Cocrystal Pharma to Participate in a Fireside Chat at the - GlobeNewswire
Kaltura to Host 2025 Investor Event - The Manila Times
Direct Access to Cocrystal Pharma Management: Key Details of Upcoming Zacks Analyst Forum - StockTitan
Aptorum Gr Stock Price, Quotes and Forecasts | NASDAQ:APM - Benzinga
Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap - ACCESS Newswire
New Information Reveals Opportunity in Volatility -- Featured Research on Norsk Hydro, Paragon Offshore, Pure Biosciences and Cocrystal Pharma - ACCESS Newswire
Global Influenza Vaccine Market is Projected to Cross USD 14 Billion Mark by 2032 | DelveInsight - The Malaysian Reserve
Cocrystal Pharma And 2 Other Promising US Penny Stocks To Watch - Simply Wall St
Honeywell International Inc’s (HON) Stock: A Long-Term Performance Analysis - The News Heater
An In-Depth Look at BP plc ADR’s (BP) Stock Performance - The News Heater
Conduit Pharmaceuticals Transitions to Phase II of Sarborg Collaboration to Support AI-Driven Drug Development - The Manila Times
Conduit's AI-Powered Drug Development Takes Major Leap: Real-Time Trial Dashboard Unveiled - StockTitan
Drugmakers prep for bird flu outbreak, despite continued low risk - PharmaVoice
Cocrystal Pharma Extends Phase 2a Influenza Drug Study Amid Lower Infection Rates, Stock Near 52-Week High - HPBL
Influenza Clinical and Non-Clinical Studies, Key Companies, - openPR
What is Northland Capmk’s Forecast for CECO FY2024 Earnings? - Defense World
HC Wainwright Forecasts Higher Earnings for Cocrystal Pharma - Defense World
EDSA: IND Expected in 2025 for EB06 for the Treatment of Vitiligo - Research Tree
Influenza Pipeline Insights, Clinical Trials Analysis, Emerging Therapies and Companies | DelveInsight - EIN News
**Cocrystal Pharma, Inc. Presents Corporate Update to Investment Community** - Defense World
Midday Market Movers: Biggest Stock Declines of the Day – Market - HPBL
Cocrystal Pharma Engages Investors with Limited Disclosure - TipRanks
Cocrystal Pharma Reports Positive Phase 1 Results with Oral Pan-Viral Protease Inhibitor CDI-988 for Norovirus and Coronavirus Infections - Defense World
Arcturus Therapeutics launches Phase I Avian Influenza trials in US - Yahoo Finance
COCP: Phase 2a Trial of CC-42344 Extended - Smartkarma
COCP: Phase 2a Trial of CC-42344 Extended… - Zacks Small Cap Research
Cocrystal Pharma Reports Positive Phase 1 Study Results - TipRanks
Cocrystal Pharma Reports Phase 1 Results with Oral, - GlobeNewswire
Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections - Yahoo Finance
Cocrystal to extend enrolment in Phase IIa influenza inhibitor trial - Yahoo Finance
CLS Holdings USA, Inc. Executes Agreement to Amend Convertible Debentures - Defense World
Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Sees Large Growth in Short Interest - Defense World
BRC Inc. (NYSE: BRCC) Amends Credit Agreements and Enters into $40 Million Term Loan Facility - Defense World
A SPAC III Acquisition Corp Announces Agreement with HD Education Group Limited - Defense World
Supermarket Income REIT (OTCMKTS:SUPIF) Shares Up 0.7% – Should You Buy? - Defense World
Cornish Metals (LON:CUSN) Shares Up 1.1% – What’s Next? - Defense World
Greenwave Technology Solutions (NASDAQ:GWAV) Stock Price Down 3.9% – Here’s What Happened - Defense World
Cocrystal Pharma, Inc. to Extend Phase 2a Influenza Challenge Study with Oral PB2 Inhibitor CC-42344 - Marketscreener.com
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):